Acute coronary syndromes refer to any constellation of clinical symptoms compatible with acute myocardial ischemia which may be life-threatening.
It encompasses unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).
Unstable angina is the ischemic discomfort that presents without persistent ST-segment elevation on ECG and without the presence of cardiac markers in the blood.
Non-ST-segment elevation myocardial infarction is diagnosed if cardiac markers are positive with ST-segment depression or with nonspecific or normal ECGs.
The patient typically presents with ischemic-type chest pain that is severe and prolonged and may occur at rest or may be caused by less exertion than previous episodes.
Lowering of resting heart rate (RHR) with bisoprolol was associated with improved composite cardiac clinical outcome (CCCO) in Asian patients who had coronary artery disease (CAD) with comorbid hypertension, according to a subgroup analysis of the BISO-CAD study presented at ACC Asia 2018 in Shanghai, China.
New-generation drug-eluting stents (DES) are superior to early-generation stents in reducing cardiovascular (CV) events and mortality out to 10 years, but there are no significant differences between new-generation stents based on biodegradable polymer and those with permanent polymer, according to the ISAR-TEST* 4 study presented at AHA 2018.
Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
The duration of dual antiplatelet therapy (DAPT) should be individualized based on ischaemic and bleeding risk of a particular patient, rather than focusing on a dualistic short- vs long-duration therapy thinking, advocates a leading expert during AFCC 2018.
Treatment with the SSRI* escitalopram for depression following a recent acute coronary syndrome (ACS) may reduce long-term risk of major adverse cardiac events (MACE), according to the EsDEPACS** study.
Low-density lipoprotein cholesterol (LDL-C) levels remained high in many patients with stable or acute coronary heart disease (CHD) in Asia, despite having a very high risk of recurrent cardiovascular (CV) events, indicating that the use of lipid-lowering therapies and lipid monitoring were inadequate.
Very early invasive coronary angiography within 12 hours does not significantly improve long-term outcomes of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) compared with the standard strategy of evaluation within 48–72 hours, according to results of the VERDICT trial reported at the European Society of Cardiology (ESC) Congress 2018.
Drug-coated balloons (DCB) are noninferior to drug-eluting stents (DES) for the management of small native coronary artery disease (CAD), according to results of the BASKET-SMALL 2 trial presented at the European Society of Cardiology (ESC) Congress 2018.
Revascularization of chronic total coronary occlusion (CTO) with the new-generation zotarolimus-eluting stents (ZES) using contemporary technique led to a favourable procedural success and improved health status and late-term clinical outcomes, hence lending support to CTO revascularization with ZES in a high-lesion, complex patient population, according to the PERSPECTIVE trial*.
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Familial hypercholesterolaemia (FH) does not lead to an elevated lipoprotein(a), suggest the results of a recent study. Rather, elevated lipoprotein(a) increases the chance that an individual with genetic FH will be clinically diagnosed.